From raw material to medicine
Medical cannabis today has supplemented, or even replaced, several preparations for muscle relaxation in multiple sclerosis (MS) and Parkinson’s for example. There is no reason to believe that developments will stop there.
We believe that cannabinoids will replace drugs that are often used to relieve symptoms in conditions such as tremor, cerebral palsy (CP), neuropathic pain, epilepsy, stress disorders and chronic fatigue syndrome (ME). Above all, we believe that medical cannabis can help to reduce the use of opiates in healthcare.
We are therefore developing and producing several human and veterinary medicines with active substances from extract, kief and liquid from the hemp plant Cannabis Sativa L +0.2% THC. These include raw materials and active pharmaceutical substances for the pharma sector, white labels for export, and production of sales-ready preparations under our proprietary brand.
Our goal is to halt and relieve patients’ illness symptoms with carefully formulated, clinically tested, diagnosis-specific medicines.
»In Sweden there is a lack of approved medicines with cannabinoid active substances. In actual fact there is only one approved preparation on the market today, and this is a poor show. We’re going to change that!”«
– Therese Nader, CEO Aureum Pharma AB
Drugs with different cannabinoid active substances are currently prescribed to a great many patients every year, and two health centres in Sweden have an explicit focus on medical cannabis for patients: Smärtcentrum Malmö and Spinalis in Stockholm.
At the end of 2019 we will start building new premises for pharmaceutical production and laboratory in Stockholm. Our aim is to build and recruit for a capacity that can store and process at least 15,000 kg of plant matter a month.
We will need to recruit personnel for several different positions, and we aim to have more than 400 employees within three years. Do you have what it takes? Check out our careers page.